Tissue Regenix appoints Daniel Lee as CEO

Writer,

Regenerative medical devices company Tissue Regenix said it had appointed Daniel Lee as chief executive.

Lee was currently the head of the company's US operations, a role he'd commenced in January 2019.

Previous to that, he was CEO of Scaffold Biologics and Aperion Biologics.

At 8:50am: (LON:TRX) Tissue Regenix Group PLC share price was 0p at 0.41p


Related content

Tissue Regenix expects annual revenue to slip 2%

Regenerative medical devices company Tissue Regenix said it expected its annual revenue to slip 2%, in what it described as a 'strong' performance against a...

Mon, 08/02/2021 - 08:05


Tissue Regenix appoints CFO

Medical devices company Tissue Regenix has appointed David Cocke as CFO and director to the board with immediate effect.

Mr Cocke has over 29...

Thu, 21/01/2021 - 08:24


Tissue Regenix makes first porcine tendon deliveries

Regenerative medical devices company Tissue Regenix said it had notched first deliveries of its porcine tendon product, with additional shipments expected in early 2021.

The...

Wed, 02/12/2020 - 07:39


Tissue Regenix losses narrow on cost cutting

Regenerative medical devices company Tissue Regenix posted a narrower first-half loss after it cut overheads.

Pre-tax losses for the six months through June amounted to...

Wed, 02/09/2020 - 07:47


Tissue Regenix enters UK distribution agreement for porcine tendon product

Regenerative medical devices company Tissue Regenix said it had entered into a distribution agreement and secured its first order with a speciality supplier of orthopaedic...

Mon, 24/08/2020 - 07:50